OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain.

英国牛津--（商业新闻短讯）--Exscientia plc（纳斯达克：EXAI）今天宣布了三篇摘要，将于10月23日至25日在西班牙巴塞罗那举行的2024年第36届EORTC-NCI-AACR（ENA）研讨会上发表。

“As our precision-designed LSD1 and MALT1 inhibitors continue to progress towards the clinic, we are excited to share new preclinical data from both programmes,” said David Hallett, Ph.D., interim Chief Executive Officer and Chief Scientific Officer of Exscientia. “These posters, as well as an additional focus on our assay development, highlight the potential of our platform to design best-in-class molecules with improved properties.

Exscientia临时首席执行官兼首席科学官David Hallett博士说：“随着我们精确设计的LSD1和MALT1抑制剂不断走向临床，我们很高兴分享这两个项目的新临床前数据。”。“这些海报以及对我们分析开发的额外关注，突显了我们平台设计具有改进性能的同类最佳分子的潜力。

As our state-of-the-art automation facility continues to ramp up in scale, we look forward to further accelerating the design and development of future molecules.”.

随着我们最先进的自动化设施规模不断扩大，我们期待着进一步加速未来分子的设计和开发。”。

The ENA posters will be available on the Exscientia website from their time of presentation.

ENA海报自发布之日起将在Exscientia网站上发布。

Poster Presentations

墙报交流

Title: Combining next-generation BTK and MALT1 inhibitors to enhance efficacy and therapeutic utility in B-cell malignancies

标题：结合下一代BTK和MALT1抑制剂以增强B细胞恶性肿瘤的疗效和治疗效用

Session Title: Combination therapies

课程名称：联合疗法

Catalog Number: 218

目录号：218

Poster Board Number: PB206

Date/Time: Thursday, October 24 / 9:00 a.m. – 5:30 p.m. CEST

日期/时间：10月24日星期四上午9:00–下午5:30 CEST

EXS73565 (‘565) is a potent, selective allosteric MALT1 inhibitor designed to have an improved safety profile, with clinical studies expected to start in early 2025

EXS73565（'565）是一种有效的选择性变构MALT1抑制剂，旨在提高安全性，临床研究预计将于2025年初开始

Combining MALT1 inhibitors, such as ‘565, with BTK inhibitors has the potential to provide enhanced efficacy in B-cell malignancies, by greater inhibition of pathogenic nuclear factor-kappa B (NF-kB) signalling and addressing BTK-resistance mechanisms

通过更好地抑制致病性核因子-κB（NF-kB）信号传导和解决BTK耐药机制，将MALT1抑制剂（例如“565”）与BTK抑制剂联合使用，有可能提高B细胞恶性肿瘤的疗效

Exscientia researchers combined ‘565 with the BTK inhibitor zanubrutinib and observed deeper, more durable efficacy responses in xenograft models of B-cell malignancies, with long-lasting tumour eradication seen for activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL)

Exscientia研究人员将565年与BTK抑制剂zanubrutinib联合使用，在B细胞恶性肿瘤的异种移植模型中观察到更深入，更持久的疗效反应，对于活化的B细胞样弥漫性大B细胞淋巴瘤（ABC-DLBCL）观察到持久的肿瘤根除

Studies also confirmed target pathway biology engagement, with ‘565 alone and in combination with zanubrutinib inhibiting NF-kB target gene expression in in vivo models

研究还证实了靶通路生物学的参与，单独使用‘565’并与扎鲁替尼联合抑制体内模型中NF-kB靶基因的表达

Overall, the selective profiles of ‘565 and zanubrutinib may maximise the therapeutic index of MALT1 and BTK inhibition in combination, providing scope for enhanced efficacy for patients with B-cell malignancies

总的来说，565和扎鲁替尼的选择性特征可以最大限度地提高MALT1和BTK联合抑制的治疗指数，为B细胞恶性肿瘤患者提供增强疗效的空间

Title: In vivo pharmacokinetics, pharmacodynamics and anti-tumour efficacy of EXS74539: A novel, reversible LSD1 inhibitor for acute myeloid leukaemia

标题：EXS74539的体内药代动力学，药效学和抗肿瘤功效：一种用于急性髓性白血病的新型可逆LSD1抑制剂

Session Title: Epigenetic modulators (HDAC bromodomain modulators, EZH2)

会议标题：表观遗传调节剂（HDAC溴结构域调节剂，EZH2）

Catalog Number: 250

目录号：250

Poster Board Number: PB238

海报板编号：PB238

Date/Time: Thursday, October 24 / 9:00 a.m. – 5:30 p.m. CEST

日期/时间：10月24日星期四上午9:00–下午5:30 CEST

‘539 is a novel, potent, selective and reversible LSD1 inhibitor, with a highly differentiated profile and designed to be brain penetrant, expected to enter the clinic in early 2025

'539是一种新型，有效，选择性和可逆的LSD1抑制剂，具有高度分化的特征，旨在成为大脑渗透剂，预计将于2025年初进入临床

The poster highlights that by combining ex vivo perturbation of primary human acute myeloid lymphoma (AML) samples with ‘539 and omics profiling, 12 potential pharmacodynamic (PD) biomarker gene candidates were identified that correlate with LSD1 inhibitor activity

海报强调，通过将原发性人类急性髓样淋巴瘤（AML）样品的离体扰动与539和组学分析相结合，鉴定出12种与LSD1抑制剂活性相关的潜在药效学（PD）生物标志物候选基因

Upregulation of the identified biomarker gene candidates was confirmed in an in vivo AML xenograft model post ‘539 treatment

539治疗后的体内AML异种移植模型证实了已鉴定的生物标志物候选基因的上调

Treatment of the in vivo model with the reversible inhibitor ‘539 resulted in limited platelet level effects, highlighting how ‘539 was designed to maximise target engagement while limiting thrombocytopenia

用可逆抑制剂‘539’治疗体内模型导致血小板水平效应有限，突出了‘539’是如何在限制血小板减少的同时最大限度地提高目标参与度的

Title: Xcellomics: Powering rapid translation of HTS outputs to AI-driven drug discovery programmes

标题：Xcellomics：推动HTS输出快速转化为人工智能驱动的药物发现计划

Session Title: Functional genomics

课程名称：功能基因组学

Catalog Number: 414

目录号：414

Poster Board Number: PB402

海报板编号：PB402

Date/Time: Friday, October 25 / 9:00 a.m. – 3:00 p.m. CEST

日期/时间：CEST，10月25日，星期五，上午9:00–下午3:00

Xcellomics is a collaboration between Exscientia and The Centre for Medicines Discovery at the University of Oxford, used to rapidly translate the results of cell-based, high-throughput screens into transformative oncology therapies

Xcellomics是Exscientia与牛津大学药物发现中心的合作，用于将基于细胞的高通量筛选结果快速转化为转化性肿瘤疗法

The collaboration has successfully identified and validated novel essential regulators of a key oncogenic pathway

该合作已成功鉴定并验证了关键致癌途径的新型必需调节剂

Automated assay development and chemical hit ID performed by Exscientia rapidly pushed these novel therapeutic targets into drug discovery programmes

Exscientia进行的自动检测开发和化学命中ID迅速将这些新的治疗靶点推进了药物发现计划

About Exscientia

关于Exscientia

Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients, faster. Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. Operating at the interfaces of human ingenuity, artificial intelligence (AI), automation and physical engineering, we pioneered the use of AI in drug discovery as the first company to progress AI-designed small molecules into a clinical setting.

Exscientia是一家技术驱动的药物设计和开发公司，致力于更快地为患者创造更有效的药物。Exscientia将精确设计与综合实验相结合，旨在以最有效的方式发明和开发尽可能最好的药物。。

We have developed an internal pipeline focused on oncology, while our partnered pipeline extends to many other therapeutic areas. By leading this new approach to drug creation, we believe we can change the underlying economics of drug discovery and rapidly advance the best scientific ideas into medicines for patients..

我们已经开发了一个专注于肿瘤学的内部管道，而我们的合作管道则扩展到许多其他治疗领域。通过领导这种药物创新的新方法，我们相信我们可以改变药物发现的潜在经济学，并迅速将最佳科学思想转化为患者的药物。。

For more information visit us on www.exscientia.com or follow us on LinkedIn @ex-scientia and X @exscientiaAI.

欲了解更多信息，请访问www.exscientia.com或通过LinkedIn@ex scientia和X@exscientiaAI关注我们。

Forward-looking Statements

前瞻性声明

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” and “projects” or similar expressions are intended to identify forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》中“安全港”条款含义内的某些前瞻性声明。诸如“预期”、“相信”、“期望”、“打算”和“项目”之类的词语或类似表达旨在识别前瞻性陈述。

All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies, PD biomarkers related to LSD1 inhibitor treatment and the benefits of reversible LSD1 inhibition on platelets as well as the ability of Exscientia’s technology to design compounds to create more effective medicines for patients.

除历史事实声明外，本新闻稿中的所有声明均为前瞻性声明。。

Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing preclinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the development and deployment of new technology and facilities; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics and the endeavour of building a business around such product candidates; and the process of creating a combined company with Recursion Pharmaceuticals and subsequent activities by any such combined company.

此类声明受到许多风险、不确定性和假设的影响，包括与Exscientia及其合作伙伴计划和正在进行的临床前研究和临床试验的启动、范围和进展以及由此产生的费用相关的风险、不确定性和假设；临床，科学，监管和技术发展；新技术和设施的开发和部署；发现、开发和商业化可用作人类治疗剂的安全有效候选产品的过程，以及围绕这些候选产品建立业务的努力；以及与Recursion Pharmaceuticals创建合并公司的过程以及任何此类合并公司的后续活动。

In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and .

鉴于这些风险和不确定性，以及Exscientia年报20-F表风险因素部分和其他部分中描述的其他风险和不确定性，与证券和。